Hot topics close

Multiple sclerosis

FDA Approves Shorter Infusion Time for MS Therapy Ocrevus
10
  • FDA Approves Shorter Infusion Time for MS Therapy Ocrevus
  • Roche gets FDA OK for multiple sclerosis treatment
  • FDA approves Roche's OCREVUS® (ocrelizumab) shorter 2-hour infusion for relapsing and primary progressive multiple sclerosis
  • Multiple Sclerosis Therapies Market Report 2020 - Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2014-2025 - ResearchAndMarkets
  • Multiple Sclerosis Therapies Market Report 2020 - Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2014-2025 - ResearchAndMarkets
  • FDA Approves Genentech's Ocrevus (ocrelizumab) Shorter 2-Hour Infusion for Relapsing and Primary Progressive Multiple Sclerosis
  • Primary Progressive Multiple Sclerosis Market Applications and Emerging Growth Factors 2020-2027
  • Multiple sclerosis trial focusing on people who can't walk begins recruitment
  • Your FAQs Answered: Does Relapsing Remitting MS Get Worse?
  • New Agents Available for Insomnia and Multiple Sclerosis
This week's most popular news